KraneShares CSI China Internet ETF vs Twist Bioscience Corp — how do they compare? KraneShares CSI China Internet ETF trades at $24.93 (market cap $4.37B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 2.3× KraneShares CSI China Internet ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Twist Bioscience Corp for 27 Days on average.
| KWEB | TWST | |
|---|---|---|
Market Cap | $4.37B | $10.08B |
Volume | 13,393,361 | 4,229,037 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $205.00 |
52-Week Low | $23.63 | $25.45 |
Typical Hold Time | 57 Days | 27 Days |
Enterprise Value | — | $10.01B |
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $24.025, down 1.25% amid bearish technical signals with all 13 moving averages indicating sell pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption, though recent institutional activity shows mixed positioning with some firms reducing stakes while others increase exposure ahead of potential trade developments.
The outlook remains cautious given China's macroeconomic pressures and ongoing U.S.-China trade tensions, though corporate profits surged 26% in Q2 2026. Key risks include global protectionism against Chinese exports and regulatory uncertainty, while potential trade agreement progress could provide catalysts for the battered Chinese internet sector.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →